HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Corneal contact time of artificial tear solutions].

Abstract
In 30 subjects without ophthalmological disease the corneal contact time of a new artificial polyacrylic-based tear gel (Vidisic, produced by Dr. Mann, Berlin) was compared with a well-known artificial polyvinyl alcohol-based tear solution. The Vidisic concentration remained in the corneal tear film 7 times longer than the substance it was compared with. In a second study including 7 normal subjects and 5 patients with keratoconjunctivitis sicca, the influence of Vidisic on break-up time (BUT) and the Schirmer test was demonstrated. It was found that tear secretion improved for 2-4 hours (Schirmer test) and the stability of the tear film (BUT) improved for about 6 hours with Vidisic. These results suggest that application of Vidisic four times a day is sufficient for efficatious therapy even in cases of severe keratoconjunctivitis sicca.
AuthorsR Marquardt, T Christ
JournalKlinische Monatsblatter fur Augenheilkunde (Klin Monbl Augenheilkd) Vol. 189 Issue 3 Pg. 254-7 (Sep 1986) ISSN: 0023-2165 [Print] Germany
Vernacular TitleUntersuchungen zur Verweildauer von Tränenersatzmitteln.
PMID3784417 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Acrylates
  • Ophthalmic Solutions
  • Surface-Active Agents
  • Wetting Agents
  • vidisic
  • Polyvinyl Alcohol
Topics
  • Acrylates (metabolism)
  • Cornea (metabolism)
  • Female
  • Humans
  • Keratoconjunctivitis Sicca (metabolism, therapy)
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Polyvinyl Alcohol (metabolism)
  • Surface-Active Agents (metabolism)
  • Tears (metabolism)
  • Wetting Agents (metabolism, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: